Page 95 - MemoriaER-Eng

www.ciberer.es

• F l, P MP, s-c l, s F, l JJ, n c, M-
Most relevant orMentiniereiraánchezenizoantacatterinaucasaVarroartínez
serrano a, cuezVa JM. (2014) In vivo inhibition of the mitochondrial H+-ATP synthase
scientific in neurons promotes metabolic preconditioning. EMBO J. 33(7):762-78.

articles
• sánchez-araGó M., García-berMúdez J., Martínez-reyes i., santacatterina F., cuezVa JM.
(2013) Degradation of IF1 controls energy metabolism during osteogenic differen-

tiation of stem cells. EMBO Rep. 14(7):638-44.

• sánchez-araGó M., ForMentini l., Martínez-reyes i., García-berMudez J., santacatterina F.,
s-c l., W iM., a M., n l., J a., l ec., c J., n-
ánchezenizoillersldeaáJerauarránzóPezloFenta
Varro c., esPinosa e., cuezVa JM. (2013) Expression, regulation and clinical relevance
of the ATPase inhibitory factor 1 in human cancers. Oncogenesis. 2:e46.

• l-e J., G J., r M., c JM., F i., c d., b J.,
óPezrauskinalinouizuezVaabreGatacabelosoada
Martínez J., Ferrer i., PaMPlona r., Villarroya F., Portero-otín M., Fourcade s., PuJol a.
(2013) Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease
á
X-linked adrenoleukodystrophy. Hum Mol Genet. 22(16):3296-305.
ó
ó
• snchez-araGó, M., ForMentini, l., cuezVa, JM. (2013) Mitochondria-Mediated Energy í

Adaption in Cancer: The H(+)-ATP Synthase-Geared Switch of Metabolism in Human
Tumors. Antioxid Redox Signal. 19(3):285-98.

PROJECTS
Highlights
Reference: BFU2010-18903. Title: Biogénesis de la mitocondria y su disfunción en

patologa. Budget: 363.000€. 2011-2013. PI: José M. Cuezva Marcos.
ó
Reference: S2010/BMD-2402. Title: La mitocondria y su implicación en patología hu-
mana. Budget: 795.800€. 2012-2015. PI: José M. Cuezva Marcos.
ó

PATENTES

Inventors: Fulvio Santacatterina, María Sánchez-Aragó and José M. Cuezva. Title: “Un
proceso y kit para el diagnstico diferencial de una enfermedad que cursa con afec-

tacin muscular”. Application number: 201230771. Publication number: ES2432653.

Country: Spain. Publication date: 23/05/2012. Applicants: Universidad Autónoma de
Madrid-CIBERER.

BRAND REGISTRY NUMBER: PROTEOmAb.

Owner: Universidad Autnoma de Madrid. Brand number: 3.055.803. Application
date: 12/12/2012. Authorization date: 14/03/2013.

The lab has developed PROTEOmAb Platform, focused on identification and quantifica-

tion of new disease molecular markers and/or therapy response. Based on “Reverse
Phase Protein Microarray” technology. Analysis of 1.000 different biopsies, that pro-

vides correlations with clinical and treatment response parameters.

(i) “Translation of Energy Metabolism” group in Cancer field of the Instituto de Inves-
tigacin Hospital 12 de Octubre (i+12)

(ii) We belong to MITOLAB Consortium, Comunidad de Madrid. J.M. Cuezva is the 13
20
Coordinator.
T
OR
ABSTRACT OF SELECTED PUBLICATIONS
P
RE
We have demonstrate that the ATPase Inhibitory Factor 1 (IF1) is expressed in hM- L
SCs but is not expressed in the differentiated cells. In a transgenic mouse model the A
NU
expression of IF1 in neurone inhibits oxidative phosphorylation and regulates the N
activity of aerobic glycolysis. This also has been demonstrated in hMSCs. Activation A
R /
of IF1 degradation acts as the switch that regulates energy metabolism during dif- E
ferentiation. We conclude that IF1 is a stemness marker important for maintaining ER
B
the quiescence state and recently IF1 has been described as a negative regulator of CI
mitochondrial respiratory defects in rare diseases (Cell Reports 7, 1-8, 2014).

95